PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
Psyomics has raised €13M across 3 funding rounds from 4 investors, most recently a Seed round in Oct 2025. Based in Cambridge, UK; founded 2015; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-10-10 | Seed | €8.6M | — | View deal → |
| 2022-06-21 | Other | €2.8M | Meltwind,Newable Ventures,Parkwalk | View deal → |
| 2020-10-27 | Other | €1.7M | Parkwalk Advisors | View deal → |
